NEWS & EVENTS

 pressreleasebutton.jpg    calendar.jpg    Newspaper white.jpg    

Click on the icon to jump down in the page

 PRESS RELEASES

SEE ALL PRESS RELEASES

Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy in Metastatic Prostate Cancer Patients

A blood test measuring the diversity of individual circulating tumor cells correlates with differential survival on chemotherapy vs. targeted hormone therapy in metastatic prostate cancer and offers potential to guide treatment choices in multiple solid tumor cancers.

Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors

Investigators from Yale, USC, UC San Diego, and Epic Sciences published findings in Cancer Epidemiology, Biomarkers & Prevention, showing that the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patients

Epic Sciences Announces Completion of $40 Million Series D Financing

Epic Sciences announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing.

Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patient blood samples is predictive of therapeutic benefit. Previous work by the same team, reported in JAMA Oncology, demonstrated that nuclear localized AR-V7 protein in CTCs was predictive of a 76 percent reduction of risk of death for mCRPC patients who received taxane chemotherapy versus Androgen Receptor Signaling inhibitors (ARSi), Zytiga and Xtandi.

Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC). In addition to profiling genome wide copy number variation (CNV) from single cells, the authors also validated the ability to characterize the extent of genomic instability within individual CTCs. The study "Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis" published today in PLOS ONE utilizing the Epic Sciences "No Cell Left Behind" CTC platform.

CALENDAR of EVENTS

SEE MORE EVENTS

SITC 2017

Society for Immunotherapy for Cancer's (SITC) 32nd Annual Meeting

AACR-NCI-EORTC

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ESMO 2017

European Society for Medical Oncology 2017 in Madrid, Spain. September 8 - 12th, 2017

Genomic Health to Market Epic Sciences’ AR-V7 Liquid Biopsy Test

NEW YORK (GenomeWeb) - Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

Test Aids Prostate Cancer Treatment

Wall Street Journal - Genomic Health will commercialize a new screening to influence choice of therapies

Guest Commentary: Back to cancer’s drawing board

By Murali Prahalad of Epic Sciences A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

Epic Sciences' Circulating Tumor Cell Prostate Cancer Test Shows Promise in New JAMA Study

CHICAGO (GenomeWeb) - A new study has demonstrated predictive power of an AR-V7 protein test.